CHM-029 / CHARM Therapeutics - LARVOL DELTA

CHARM Therapeutics advances CHM-029, a next-generation menin inhibitor designed to overcome resistance mutations, as its first clinical candidate for acute myeloid leukaemia (AML) (GlobeNewswire) - "AI-discovered candidate CHM-029 demonstrates robust, dose-dependent tumor regression in pre-clinical AML models and retains potency against all known resistance mutation. First-in-human trials expected to begin in Q2 2026."

First-in-human • New trial • Preclinical • Acute Myelogenous Leukemia